Description
SKLB610 is an inhibitor of VEGFR2 that also inhibits PDGFR and FGFR2. SKLB610 exhibits anticancer chemotherapeutic and anti-angiogenic activities. In animal models of colorectal cancer and non-small cell lung cancer (NSCLC), SKLB610 decreases capillary tube formation, microvessel density, and tumor proliferation.